r-tpa合并甘露醇治疗血管壁病变性脑梗死的临床疗效分析

Clinical Effect of r-tpa Combined Mannitol in Treatment of Cerebral Infarction Caused by Vascular Diseases

目的:观察r-tpa合并甘露醇治疗血管壁病变性脑梗死临床疗效。方法:将临床发病6 h以内的急性脑梗死患者随机分为治疗组与对照组,每组60例,治疗组用r-tpa合并甘露醇静脉滴注,对照组用川芎嗪注射液静脉滴注,对治疗组和对照组连续使用15天观察对照组和治疗组的临床疗效及神经功能恢复情况。结果:采用r-tpa合并甘露醇静脉滴注和川芎嗪静脉注射液疗效比较,治疗组总有效率93.33%,明显优于常规治疗组78.33%,两组差异有统计学意义(P<0.05)。两组患者治疗后CSS评分均显著低于治疗前,且治疗组明显低于对照组(P<0.05);两组患者治疗后ADL评分均显著高于治疗前,且治疗组明显高于对照组(P<0.05)。结论:r-tpa合并甘露醇治疗血管壁病变性脑梗死临床疗效显著,且对6个小时内没有出血倾向的血管病变性脑梗死安全实用,患者后期恢复效果良好。

Objective： To explore the clinical effect of r-tpa combined mannitol in treatment of cerebral infarction caused by vascular diseases. Methods： The patients with acute cerebral infarction（ACI） within 6 hours were randomly divided into treatment group and control group with 60 cases in each group. The patients in treatment group accepted r-tpa combined mannitol, and the patients in control group accepted ligustrazine injection. The clinical efficacy and recovery of neurological function were measured after 15 days treatment. Results： The clinical effect of treatment group was 93.33 %, which was obviously higher than 78.33 % of control group with statistically significance（P〈0.05）. The CSS scores of two groups after treatment were obviously lower than before, and the treatment group was much lower than control group（P〈0.05）. The ADL scores of two groups after treatment were obviously higher than before,and the treatment group was much higher than control group（P〈0.05）. Conclusions： Using r-tpa combined mannitol has good effect in treatment of cerebral infarction caused by vascular diseases, which is safe and good at symptom improvement of later stage.